Sanara MedTech Inc. Partners with Biomimetic Innovations for OsStic™
Sanara MedTech Inc. (Nasdaq: SMTI), a forward-thinking medical technology company, has recently joined forces with Biomimetic Innovations Ltd (BMI) to provide an exciting update regarding the innovative product, OsStic™. This strategic partnership is paving the way for OsStic™'s introduction to the U.S. market, targeted for the first quarter of 2027, following the completion of crucial milestones and receiving FDA clearance.
Unlocking the Potential of OsStic™
OsStic™ is a groundbreaking synthetic injectable structural bio-adhesive designed specifically for provisional fixation treatments. It holds the potential to revolutionize how the medical community addresses the over 100,000 peri-articular fractures that occur annually in the U.S. The significance of this product cannot be overstated, especially considering the FDA granted it Breakthrough Device Designation in December 2023. This recognition reflects the product's capability to significantly improve treatment for life-threatening fractures.
Key Benefits of OsStic™
The unique formula of OsStic™ includes ingredients such as phosphoserine, alpha-tricalcium phosphate (?-TCP), and calcium silicate, which work together to enhance bone healing. Based on preclinical testing, OsStic™ is anticipated to offer bonding strength forty times greater than traditional calcium phosphate bone cement, addressing major limitations posed by current fixation techniques. The quick-setting nature of OsStic™ allows it to seamlessly integrate with bone tissue, effectively molding and remodeling as needed in real-time.
A Game-Changer for Orthopaedic Surgery
Experts within the orthopaedic field are buzzing with enthusiasm about OsStic™. Dr. J. Tracy Watson, a prominent trauma surgeon, highlighted the clinical necessity for innovative solutions to complex joint reconstructions. He explained that existing technologies often fail to restore joint stability in complicated cases. With OsStic™, surgeons can achieve micro-stability that was previously considered impossible, bridging the gap for patients who would otherwise face more invasive measures.
Progress and Milestones in Development
Throughout 2025, Sanara and BMI have achieved several key milestones in product development, clinical trials, and regulatory approvals. Furthermore, the U.S. Patent and Trademark Office has granted a patent recognizing the innovation behind OsStic™, effectively securing its future use in multiple clinical applications until 2037. This strategic protection ensures that Sanara can advance OsStic™ along with its related technologies efficiently.
The Strategic Alliance
In January 2025, Sanara announced a pivotal agreement with BMI to exclusively market and distribute OsStic™ across the U.S. This partnership leveraged Sanara’s financial investment and BMI’s technical expertise for mutual benefit. The agreement establishes a solid foundation for both companies to thrive in the competitive medical technology sector.
The Path Ahead
Seth Yon, President and CEO of Sanara, emphasized their dedication to delivering groundbreaking solutions within the surgical market. Partnering with BMI enhances their capability to meet critical demands in orthopaedic care, which is vital for establishing Sanara as a leader in surgical innovation. Mark McMahan, Chief Commercial Officer of BMI, mirrored this sentiment, expressing excitement for the collaboration and the anticipated impact of OsStic™ on patient care.
About Sanara MedTech Inc.
Sanara MedTech Inc. is dedicated to developing innovative technologies aimed at improving clinical outcomes while minimizing healthcare costs in the surgical realm. The company prioritizes the distribution of surgical products designed for use by professionals within hospitals, continually striving to offer effective solutions that enhance patient care.
Frequently Asked Questions
What is OsStic™?
OsStic™ is a synthetic injectable structural bio-adhesive designed for provisional fixation in bone fractures, aimed at improving surgical outcomes.
When will OsStic™ be available in the U.S.?
OsStic™ is expected to be launched in the U.S. market in the first quarter of 2027, pending FDA clearance.
What makes OsStic™ different from traditional bone cements?
OsStic™ offers significantly stronger bonding than traditional calcium phosphate cements and integrates rapidly with bone tissue for better repair outcomes.
Who conducted the research on OsStic™?
The product's development and testing were carried out in collaboration with professionals and institutions specializing in orthopaedic surgery and medical devices.
What is the strategic partnership between Sanara and BMI?
Sanara entered a strategic alliance with BMI to license and distribute OsStic™, combining their resources to enhance product availability and market presence.
